Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized observer-blind study of M72/AS01E tuberculosis vaccine in adults with tuberculosis disease
2012-001820-36Phase 2Terminated
- Sponsor
- GSK
- Start
- Aug 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of M72 + AS01E in Tuberculosis (TB) (2 arms), sponsored by GSK. Primary endpoint: Occurrence of solicited adverse events. Started Aug 2012; status: terminated.
02
Drugs
M72 + AS01E
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on 2012-001820-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001820-36.